Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
28 April 2026
Quarterly Activities Report & Appendix 4C
For the Period Ending 31 March 2026
SPONTAN Phase II Recruitment Completed; Interim pharmacokinetic (PK) Data
Expected Q2 CY2026; Final Results to Follow
Highlights
• SPONTAN Phase II pharmacokinetic study recruitment complete; dosing of final cohort advanced
during the quarter, with interim PK data expected Q2 CY2026.
• Phase I SPONTAN data accepted for podium presentation at the World Meeting on Sexual Medicine
2026, providing international scientific validation.
• SPONTAN continues to demonstrate positive real-world outcomes, including in younger men with
performance-related erectile difficulties.
• ROXUS US commercial partner discussions progressing via the FDA 503(a) personalised medicine
pathway.
• Cash balance of A$24.1 million at 31 March 2026, debt-free, supporting upcoming clinical readouts,
US commercial strategy execution, and regulatory development.
LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”), a company focused on improving men’s health
through clinical development and commercialisation of innovative nasal spray treatments for erectile dysfunction
(“ED”), SPONTAN®
and ROXUS®
, is pleased to provide its Appendix 4C and an overview of its activities for the period
ended 31 March 2026 (the “Reporting Period” or the “Quarter”).
Commenting on the activity for the Quarter, Executive Chairman, Lee Rodne, stated:
“During the quarter, LTR Pharma progressed SPONTAN into the dosing phase of its Phase II study, with
pharmacokinetic data expected in Q2 CY2026 to support the FDA 505(b)(2) pathway. In parallel, commercial
discussions for ROXUS US market entry via the 503(a) continue to progress, with a disciplined focus on partner
selection and commercial terms.”
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
Milestone Timeline
Key milestones expected in the near term and their strategic impact are summarised below:
Program Milestone
Expected
Timing
Strategic Impact
SPONTAN
Phase II pharmacokinetic
Interim data readout
Q2 CY2026
Key clinical inflection point supporting FDA
505(b)(2) pathway
SPONTAN
Human factors study
completion
H1 CY2026
Required combination product evidence for
FDA submission
SPONTAN Leachables study completion H1 CY2026
Finalises CMC package supporting 505(b)(2)
submission
SPONTAN
Phase II Final Data Report,
Analysis, and future prescribing
information
Q3
CY2026
Supports regulatory package, Phase III
planning
SPONTAN
SAS prescribing and real-world
evidence generation
Ongoing
Expanding prescriber adoption and real-
world data
ROXUS
Progression of US commercial
discussions (503(a) pathway)
H1 CY2026
Potential US early-access commercial
pathway via the 503(a) personalised
medicine framework, subject to partner
selection and commercial terms
Operational Update
During the quarter, LTR Pharma continued to execute against its clinical development and commercialisation
priorities across both lead products.
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
Clinical Development – SPONTAN
Patient recruitment for the SPONTAN Phase II pharmacokinetic study commenced in January 2026 and was
completed in March 2026 (ASX announcements: 13 January 2026 and 5 March 2026), enrolling 27 participants
across three cohorts, including approximately 50% aged 65 years or older in alignment with FDA geriatric-use
considerations. Following enrolment, the final cohort commenced a 15-day residential dosing period during the
quarter.
The Company also received international scientific validation of its clinical profile, with Phase I data accepted for
podium presentation at the World Meeting on Sexual Medicine 2026 in Porto, to be delivered by Scientific Advisory
Board member Professor Eric Chung (ASX announcement: 8 January 2026). The study demonstrated faster drug
absorption and higher dose-normalised bioavailability relative to oral vardenafil, with a well-tolerated safety
profile, supporting the Company's regulatory strategy and clinical positioning ahead of potential US market entry.
Commercialisation – ROXUS
During the quarter, LTR Pharma continued to advance its US commercialisation strategy for ROXUS via the FDA
503(a) pathway.
Commercial partner discussions progressed during the Quarter. The Company remains disciplined in its approach
to partner selection and is focused on securing terms that support sustainable long-term value creation.
As previously disclosed, the Company has been targeting initial US sales in H1 CY2026; however, timing remains
dependent on finalisation of commercial agreements and partner onboarding.
The Company is assessing multiple potential commercial pathways for US market entry.
Market Validation & Real-World Evidence
Prescribing under the TGA Special Access Scheme continued at a consistent pace during the quarter, expanding
the real-world data beyond the 1,000+ cumulative prescriptions previously reported.
During the quarter, an independent observational case series reported positive real-world outcomes from
SPONTAN use in five younger men experiencing situational erectile difficulties associated with performance
anxiety (ASX announcement: 2 February 2026). The observations were preliminary and self-reported, not derived
from a controlled clinical study. The Company is evaluating the potential for a clinician-initiated study in this
patient population, which published literature suggests may affect 9–25% of men.
Financial Position
LTR Pharma maintained a strong financial position during the Quarter, with a cash balance of A$24.1 million as at
31 March 2026 and zero debt, providing a continued runway to execute strategic objectives across Australian and
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
US markets. Net operating cash outflow for the Quarter was A$1.8 million, reflecting ongoing disciplined
investment in the SPONTAN Phase II pharmacokinetic study, ROXUS US commercialisation activities and broader
regulatory and development activities. Based on current operating cash outflows, the Company has an estimated
funding runway of approximately 13 quarters.
Receipts of A$34,827 represent SPONTAN prescriptions issued under the TGA Special Access Scheme (SAS), which
is not a commercial sales program. SAS prescribing continues to provide valuable real-world insights that inform
the Company's clinical, regulatory and commercial planning.
In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1
of Appendix 4C totalled A$168,000, comprising Director fees, salary and superannuation for the Executive
Chairman and Non-Executive Directors.
The Company's robust financial position provides confidence in executing planned activities, including the
SPONTAN Phase II pharmacokinetic data readout in Q2 CY2026, progression of ROXUS commercial preparations,
the human factors and leachables studies, and continued real-world evidence generation through the Australian
SAS programme.
This announcement has been approved by the Board of Directors.
- ENDS –
About LTR Pharma
LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant
unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully
commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing
regulatory pathways in the US and other key markets.
LTR’s lead products, SPONTAN®
and ROXUS®
, are fast-acting intranasal sprays for the treatment of erectile
dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is
now advancing OROFLOW®
, a novel intranasal spray under development for the treatment of Oesophageal
Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.
Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated,
patient-centric treatments that enhance quality of life.
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
LTR Pharma Investor Centre
Stay informed with LTR Pharma’s latest announcements and
market updates by visiting our Investor Centre or scan the QR code.
For further information please contact:
Media Enquiries Investor Enquiries
Haley Chartres Peter McLennan
haley@hck.digital investors@ltrpharma.com
Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 6
+ See chapter 19 of the ASX Listing Rules for defined terms.
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
LTR Pharma Limited
ABN
Quarter ended (“current quarter”)
March 2026
Consolidated statement of cash flows Current quarter
$A
Year to date
(9 months)
$A
1. Cash flows from operating activities
34,827 106,627
1.1 Receipts from customers
1.2 Payments for
(839,431) (3,283,700)
(a) research and development
(b) product manufacturing and operating
costs
-
(c) advertising and marketing (169,917) (573,693)
(d) leased assets -
(e) staff costs (716,859) (2,003,378)
(f) administration and corporate costs (349,317) (1,493,394)
1.3 Dividends received (see note 3) -
1.4 Interest received 197,100 612,808
1.5 Interest and other costs of finance paid (1,225) (1,342)
1.6 Income taxes paid -
1.7 Government grants and tax incentives - -
1.8 Other (provide details if material) -
1.9 Net cash from / (used in) operating
activities
(1,844,820) (6,636,071)
2. Cash flows from investing activities
- -
2.1 Payments to acquire or for:
(a) entities
(b) businesses - -
(c) property, plant and equipment - -
(d) investments (25,000) (1,105,000)
(e) intellectual property - -
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 7
+ See chapter 19 of the ASX Listing Rules for defined terms.
Consolidated statement of cash flows Current quarter
$A
Year to date
(9 months)
$A
(f) other non-current assets - -
2.2 Proceeds from disposal of:
- -
(a) entities
(b) businesses - -
(c) property, plant and equipment - -
(d) investments - -
(e) intellectual property - -
(f) other non-current assets - -
2.3 Cash flows from loans to other entities - -
2.4 Dividends received (see note 3) - -
2.5 Other (provide details if material) - -
2.6 Net cash from / (used in) investing
activities
(25,000) (1,105,000)
3. Cash flows from financing activities
- -
3.1 Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2 Proceeds from issue of convertible debt
securities
- -
3.3 Proceeds from exercise of options - -
3.4 Transaction costs related to issues of
equity securities or convertible debt
securities
- -
3.5 Proceeds from borrowings - -
3.6 Repayment of borrowings - -
3.7 Transaction costs related to loans and
borrowings
- -
3.8 Dividends paid - -
3.9 Other (provide details if material) - -
3.10 Net cash from / (used in) financing
activities
- -
4. Net increase / (decrease) in cash and
cash equivalents for the period
25,937,281 31,808,532
4.1 Cash and cash equivalents at beginning of
period
4.2 Net cash from / (used in) operating
activities (item 1.9 above)
(1,844,820) (6,636,071)
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 8
+ See chapter 19 of the ASX Listing Rules for defined terms.
Consolidated statement of cash flows Current quarter
$A
Year to date
(9 months)
$A
4.3 Net cash from / (used in) investing activities
(item 2.6 above)
(25,000) (1,105,000)
4.4 Net cash from / (used in) financing activities
(item 3.10 above)
- -
4.5 Effect of movement in exchange rates on
cash held
- -
4.6 Cash and cash equivalents at end of
period
24,067,461 24,067,461
5. Reconciliation of cash and cash
equivalents
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
Current quarter
$A’000
Previous quarter
$A’000
5.1 Bank balances 24,067,461 25,937,281
5.2 Call deposits - -
5.3 Bank overdrafts - -
5.4 Other (provide details) - -
5.5 Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
24,067,461 25,937,281
6. Payments to related parties of the entity and their
associates
Current quarter
$A
6.1 Aggregate amount of payments to related parties and their
associates included in item 1
168,000
6.2 Aggregate amount of payments to related parties and their
associates included in item 2
-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 9
+ See chapter 19 of the ASX Listing Rules for defined terms.
7. Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A
Amount drawn at
quarter end
$A
7.1 Loan facilities - -
7.2 Credit standby arrangements - -
7.3 Other (please specify) - -
7.4 Total financing facilities - -
7.5 Unused financing facilities available at quarter end -
7.6 Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8. Estimated cash available for future operating activities $A
8.1 Net cash from / (used in) operating activities (item 1.9) (1,844,820)
8.2 Cash and cash equivalents at quarter end (item 4.6) 24,067,461
8.3 Unused finance facilities available at quarter end (item 7.5)
8.4 Total available funding (item 8.2 + item 8.3) 24,067,461
8.5 Estimated quarters of funding available (item 8.4 divided by
item 8.1)
13
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1 Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer:
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer:
8.6.3 Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer:
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 10
+ See chapter 19 of the ASX Listing Rules for defined terms.
Compliance statement
1 This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.
28 April 2026
Date: ...................................................................................
The Board of Directors
Authorised by: ...................................................................................
(Name of body or officer authorising release – see note 4)
Notes
1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
Share your feedback
Discover